Team


We are a diverse and dynamic team working with an international background and in collaboration with outstanding and globally recognized scientific experts to transform therapeutic approaches in oncology.

 

 

Founders


Dr. Stefan Ameres
Founder & Scientific Advisor

is a Molecular Biologist and since 2012 Group Leader at the IMBA, Vienna. He received a PhD in 2004 at the Max F. Perutz Laboratories at the University of Vienna, Austria, and undertook his postdoctoral research at the University of Massachusetts Medical School, MA, USA. Stefan has published more than thirty highly regard papers in leading journals with over 3000 citations and delivered more than 60 oral presentations at international conferences. Stefan received several prestigious awards and grants, including the Houska Award (B&C Private Foundation, 2018) and three ERC Grants. In 2016 he was selected as EMBO Young Investigator, and he has been an elected member of the Austrian Academy of Sciences (Young Academy) since 2015.

Dr. Johannes Zuber
Founder & Scientific Advisor

is a Medical Doctor and since 2011 Group Leader at the IMP, Vienna. Following his MD graduation in 2003 and a clinical residency at the Charité University Hospital in Berlin, Germany, he undertook postdoctoral research at Cold Spring Harbor Laboratory (CSHL), NY, USA. His outstanding scientific achievements are recorded in over 160 publications in leading peer review publications with over 8000 citations and 80 oral presentations at international conferences. Johannes has received two ERC Grants (2013, 2019), has been selected as an EMBO Young Investigator in 2014, and won the German Cancer Award (Deutscher Krebspreis) in 2016. In 2020, he has been promoted to Senior Scientist at the IMP.

Management


 

Dr. Dieter Nachtigall
Chief Executive Officer (CEO)

has 23 years of professional experience in global pharmaceutical R&D comprising the whole value chain from late research and early development stage through successful submission and approval of several products.

With a background in General Chemistry and a PhD in Analytical Chemistry he held positions at Boehringer Ingelheim as head of several analytical drug product laboratories, as R&D Project Leader and Core Team member R&D, and for more than 10 years in senior executive roles as Vice President for Quality Management and Analytical Development. He has worked extensively in development of small and large molecules (NCEs, NBEs) in an international setting with collaborations in Europe, USA, and Asia.

Since 2018 he runs his own Organizational Development / Project Coaching consulting business and joined the founders of QUANTRO at the time of inception preparation. As of April 2020 he has been appointed CEO of QUANTRO.

Advisory Board


Dr. Sebastian Kreuz
Boehringer Ingelheim Venture Fund

Dr. Dirk Ullmann
Evotec SE

Dr. Stefan Ameres
Founder

Sebastian Kreuz

studied Technical Biology in Stuttgart (Germany) and holds a PhD in molecular biology and immunology. With more than 15 years of experience in drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities.

Sebastian started his industrial career in 2004 by joining Boehringer Ingelheim (BI) as a research scientist in the functional genomics group, where he established novel experimental platforms based on RNAi and viral vectors for exploration of early drug targets. In the following years, Sebastian held various positions within BI’s R&D organization thereby further broadening his expertise in pharmacology and translational research.

From 2015 to 2019, Sebastian joined BI’s newly formed Research Beyond Borders department to implement a platform concept for virus-based gene therapy as a novel treatment modalitiy for BI. During this time he also established a global collaboration network in the gene therapy space with collaborations in Europe, China and the US.

Sebastian joined the BI venture fund (BIVF) in June 2019. In addition to Quantro Therapeutics, he serves as a board member of Abalos Therapeutics GmbH and Rewind Therapeutics NV.

Dirk Ullmann

has more than 22 years’ experience in drug discovery research and collaborative business. In his role as Global Head of Drug Discovery Services he oversees the operational business together with core responsibility for the scientific strategy of the company in Hit Identification, Structure-based Drug Discovery, Protein and Cellular Sciences, ADME-Tox and DMPK, Compound Management, Proteomics and Metabolomics.

Before joining Evotec he held a position as Chief Scientific Officer at Proteros, Munich after initial 11 years with Evotec before. Dirk Ullmann obtained his PhD in Chemistry and Biochemistry from the University of Leipzig, Germany on protease-catalyzed peptide synthesis and did his dost-doctoral training on protein engineering at Brandeis University, Waltham MA, (USA).

Stefan Ameres

is a Molecular Biologist and since 2012 Group Leader at the IMBA, Vienna. He received a PhD in 2004 at the Max F. Perutz Laboratories at the University of Vienna, Austria, and undertook his postdoctoral research at the University of Massachusetts Medical School, MA, USA. Stefan has published more than thirty highly regard papers in leading journals with over 3000 citations and delivered more than 60 oral presentations at international conferences. Stefan received several prestigious awards and grants, including the Houska Award (B&C Private Foundation, 2018) and three ERC Grants. In 2016 he was selected as EMBO Young Investigator, and he has been an elected member of the Austrian Academy of Sciences (Young Academy) since 2015.

Contact

Job Offers

i

Imprint

QUANTRO Therapeutics GmbH
Dr. Bohr-Gasse 7
A-1030 Vienna, Austria

+43 664 9158111

© QUANTRO Therapeutics GmbH